Cetuximab (Erbitux), an anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody used in the treatment of head and neck and colorectal cancer, so far faces no biosimilar challengers. However, Chinese researchers are reporting positive preclinical results for a proposed biosimilar, APZ001.
Cetuximab (Erbitux), an anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody used in the treatment of head and neck and colorectal cancer, so far faces no biosimilar challengers. However, Chinese researchers are reporting positive preclinical results for a proposed biosimilar, APZ001.
Previous studies have demonstrated that APZ001 has the same therapeutic effects as the reference product in a mouse model, and a pharmacokinetic (PK) assessment in Cynomolgus monkeys showed that the 2 products have similar PK, toxicology, and immunogenicity.
Click to read more about cetuximab.
In the current study's observation of mouse behavior, both the reference and biosimilar showed negative effects in terms of nervous excitability, autonomic and nonautonomic nervous function, nervous-muscle function, and coordination function. There was no significant difference in negative behavior between mice given the 2 drugs, however.
In an evaluation of the 2 drugs in Cynomolgus monkeys, no significant differences were recorded in heart function, though monkeys given APZ001 showed insignificant differences in heart rate and blood pressure from those given the reference, under anesthesia. No differences were observed between breath parameters or electrocardiogram results.
There were also no significant differences observed in drug-related urinary volume alteration between monkeys administered the 2 drugs. During periods of drug administration and recovery in rabbits, no abnormal reactions were observed in animals receiving either product.
In human tissues, both APZ001 and the reference showed positive signals in endocardium, alveolar epithelial cells, and surrounding vessels, and showed negative results in kidney and liver tissues.
The investigators concluded that, in their safety assessment and bioequivalence study of the 2 products, APZ001 and the reference showed highly similar effects in the animal models, and no severe adverse events were observed in any of the tested animals. APZ001, they conclude, may be a viable biosimilar for cetuximab.
Reference
Wang X, Guo J, Deng X, et al. Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models. Acta Cir Bras. 2018;33(8): 690-702. doi: 10.1590/s0102-865020180080000005.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.